Mochi Health review 2026: the marketplace play, examined

Mochi Health is the consumer brand of Mochi Health Corp., a telehealth platform launched to serve compounded-GLP-1 weight-loss patients. The platform itself does not deliver clinical care. As Mochi's own footer states, "all professional medical services are provided by licensed physicians and clinicians affiliated with independently owned and operated professional practices. Mochi Health Corp. provides administrative and technology services to affiliated medical practices it supports, and does not provide any professional medical services itself."

This admin-platform / affiliated-medical-practice split is standard for cash-pay telehealth. Federal court records identify the affiliated entities as Mochi Medical CA PC (the California professional corporation) and Mochi Medical PA (the Texas-style professional association) — both named as co-defendants in the Eli Lilly federal lawsuit (see section 06).

The product model is what makes Mochi distinctive in our set. Where most competitors connect a patient to whichever clinician is available in their state and to a single in-house or contracted pharmacy, Mochi presents a marketplace: after the eligibility quiz, the patient picks the healthcare provider whose schedule and style fit them, and then picks the pharmacy they want their prescription routed to. The nutrition layer is also marketed as part of the membership rather than à la carte — with a catch on the dietitian, covered in § 08.

The headline category is compounded GLP-1 weight loss. The home page mentions skincare, hair growth, mental health, and pediatrics as additional services, and a Longevity line sells compounded sermorelin from $199 (500mcg) and compounded NAD+ as an injection from $135 (100mg), a nasal spray from $83 or a cream from $54, each on top of the membership. The product pages do not say what period those figures cover. Two copper-peptide products in the same line are labelled cosmetic rather than prescription.

None of this is the product the company is selling against: the pricing it foregrounds is for compounded injectable semaglutide and compounded injectable tirzepatide.

Mochi's pricing structure is two-component: a Mochi Health membership (the platform layer with provider access and care-team support) plus a separate per-month medication cost that depends on the dose. The drug pages show the medication price — "Medication price $60 /mo + Mochi Membership" — but not the membership fee, which is published in the FAQ. The all-in monthly number isn't foregrounded anywhere.

Prices current as of 6 October 2026, taken from Mochi Health's medication pages and FAQ. We re-verify pricing periodically; Mochi cut its compounded medication prices sharply in August 2026.

Mochi Health Membership

The membership covers unlimited appointments with your provider and 24/7 care-team support; medication is not included. Mochi's current promo: "Get $79 off your membership — first month free on our 1-month plan," limited to first-time membership purchases by new users, with medication not included.

Medication (on top of membership)

Mochi's FAQ: "Mochi prices by dose, so your medication cost depends on the weekly dose your provider prescribes. Compounded semaglutide starts as low as $60/month and compounded tirzepatide as low as $90/month." Until August 2026 these were $99 and $199.

Effective all-in monthly cost. On the monthly plan at the lowest dose, compounded semaglutide comes to $60 + $79 = $139/mo and tirzepatide to $90 + $79 = $169/mo — the same figures as our Price Index. Higher doses cost more. A new member on the promo pays only the medication in the first month. The recurring $79 membership is the kind of charge a patient might mentally treat as a one-time signup fee rather than an indefinite monthly add-on. Worth knowing.

Multi-month membership commitments. Prepaid plans lower the membership to as little as $49 a month (12 months, $588 up front). We did not check Mochi's cancellation and refund terms for prepaid plans; read them before committing.

Insurance / FSA / HSA / BNPL. Mochi now runs a separate insurance track, "Covered With Mochi" (6 months $119, 12 months $199), with visits billed through the patient's insurance and the copay shown before signing up; whether medication is covered depends on the plan. Mochi's FAQ says an HSA or FSA account can pay for the membership. We found no buy-now-pay-later option (Klarna, Affirm, Afterpay) on the site.

Mochi describes the funnel as four steps, lighter on quoted timelines than most competitors.

Eligibility quiz. A short questionnaire establishes whether the patient is a candidate for the platform's care.

Pick a provider. The marketplace step: choose a healthcare provider whose schedule and style fit you, from a pool the platform makes visible after the quiz. This is the distinctive bit — most competitors don't expose provider choice at this stage.

Pick a pharmacy. The patient selects from "pharmacies you trust." The marketplace claim is that Mochi works with multiple compounding pharmacies and lets the patient pick which one ships their prescription. The specific in-network pharmacies are not publicly disclosed by name on the homepage.

Ongoing support. In Mochi's words, "ongoing guidance from your medical provider, nutrition & wellness provider, and care team throughout your journey."

Shipping. Mochi's FAQ states: "Prescriptions can take up to 10 days for delivery. Most people receive them in less time." A separate FAQ acknowledges that GLP-1 medications "may remain stable at room temperature for up to 28 days" and that "each of our partner pharmacies performs their own stability testing" — reassurance copy for the thawed-ice-pack complaints common in compounded-GLP-1 logistics.

Mochi's weight-loss outcomes ride on the underlying molecules. The honest question is what compounded semaglutide and tirzepatide can do, and what's realistic.

For semaglutide, the STEP 1 trial found adults with overweight or obesity lost on average 14.9% of body weight at 68 weeks on once-weekly 2.4 mg semaglutide, versus about 2.4% on placebo, both arms paired with lifestyle support. For tirzepatide, the SURMOUNT-1 trial showed larger average losses — into the 20%+ range at the higher doses over 72 weeks. Weight regain after stopping is well-documented; the STEP 1 extension trial found participants regained roughly two-thirds of the weight they had lost within a year of discontinuing semaglutide.

Two honest caveats. First, every one of those trials studied branded, FDA-approved semaglutide or tirzepatide at defined doses. Mochi dispenses compounded versions, which are not the studied products and are not FDA-reviewed for safety or efficacy. The expectation is that the same active molecule behaves similarly, but that's an inference, not trial data.

Second, a study of the FDA's FAERS adverse-event database found higher reporting odds of nausea, abdominal pain, gallbladder inflammation and hospitalization for compounded GLP-1s than for branded ones (reports from 2018 to 2024), and Novo Nordisk has reported to FDA compounded sublingual samples testing far from their labeled strength. This is a category-level signal, not a Mochi-specific one, but it belongs in any reader's mental model.

Mochi's home page foregrounds several quantitative outcome claims: "10% weight loss is achieved in six months for over half of our members," "36 pounds is the average weight loss for our members in their first year," "5/6 of our members stay at least a second month," and "patients achieve an average weight loss of 16% in their first year." These are presented prominently — separate hero panels — but none of them are footnoted to a study, audit, or external source. They are uncited company-marketing claims.

Under our editorial standards, claims of this kind are recorded as what the company says but not propagated as evidence of outcomes. The branded-drug pivotal trials above are the actual evidence base for what these medications can do.

GLP-1 therapy is a well-characterized drug class, and the side-effect profile is consistent across providers. The most common effects are gastrointestinal: nausea, reduced appetite, constipation or diarrhea, and mild digestive discomfort, typically most noticeable when starting or stepping up a dose and often easing with time and dose adjustment. Less common but more serious risks documented for the class include pancreatitis and gallbladder problems. Branded GLP-1s carry a boxed warning based on rodent studies of thyroid C-cell tumors, and are not recommended for people with a personal or family history of medullary thyroid carcinoma or MEN2. Pregnancy is a contraindication.

Mochi's FAQ lists the common milder effects ("GI issues like nausea, constipation, diarrhea, and heartburn") but doesn't foreground the more serious contraindications on the home page — a prescribing provider is supposed to screen for them at intake, and patients should raise their history directly.

One Mochi-specific item worth flagging: the platform offers a pediatric line. Its pediatrics page promises "provider-guided GLP-1 and wellness treatments" for children and teens, names a pediatrician, and leaves out everything a parent would need to judge it: no age range, no BMI criteria, no list of which medications (branded or compounded) are used for minors, and no consent policy.

GLP-1 prescribing to children is an elevated regulatory and editorial sensitivity. Anyone considering Mochi for pediatric weight management should ask specifically about BMI thresholds, age cutoffs, parental consent flow, and the prescribing provider's pediatric credentials.

None of this is unique to Mochi at the GLP-1 level — it's the category's standard risk picture — but a thorough review should state it.

The single most important context for any compounded-GLP-1 provider in 2026 is the regulatory squeeze. The FDA removed tirzepatide from its shortage list in December 2024 and semaglutide in February 2025; the 503A grace period ended 22 April 2025 and the 503B grace period 22 May 2025. On 30 April 2026 the agency proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List permanently, with public comment open until 29 June 2026, later extended to 30 July 2026.

As of 7 October 2026 the FDA had published no final decision, so the exclusion is still a proposal. The practical effect is that mass-compounding of these drugs no longer rests on a shortage justification; what remains is narrower, patient-specific compounding. Mochi's two named medications — compounded semaglutide and compounded tirzepatide — are inside the proposed exclusion scope.

Mochi does not foreground 503A versus 503B language on the home page. The marketplace pharmacy model — patients "pick a pharmacy you trust" from a panel of partners — assumes the patient can make an informed choice between options. But the in-network pharmacies are not publicly named, their 503A/503B classifications are not posted, and the patient has no way to compare them at the marketing-page level. Whether that opacity changes inside the onboarding flow is unclear to us and worth verifying with the company directly.

Two concurrent manufacturer lawsuits. Mochi is a defendant in parallel federal suits from both GLP-1 manufacturers.

(1) Eli Lilly federal lawsuit (filed 23 April 2025). Per NPR reporting, Lilly's complaint against Mochi specifically alleges that Mochi "switched its patients to compounded tirzepatide with different additives, like niacinamide" and that the company changed patient doses "at least five times in just eight months" to keep selling compounded tirzepatide. Lilly sued Henry Meds, Willow Health, and Fella Health and Delilah the same day, in separate cases. In this one the co-defendants are Mochi Medical CA PC, Mochi Medical PA and, in the current complaint, Aequita Pharmacy LLC and Aequita Corporation. U.S. District Judge Jacqueline Scott Corley dismissed Lilly's first complaint in 2025 and, in April 2026, let the amended complaint go forward on its Lanham Act and California unfair-competition claims. On 8 September 2026 she ruled on the defendants' motion to dismiss the second amended complaint, granting it in part and denying it in part, so the case continues.

(2) Novo Nordisk lawsuit. Novo Nordisk sued Mochi on 4 August 2025 in the Northern District of California (Novo Nordisk A/S v. Mochi Health Corp., No. 5:25-cv-06563), under the same false-advertising statute, the Lanham Act. Novo amended its complaint in October 2025, which ended Mochi's first motion to dismiss as moot. The public docket shows no dismissal or settlement; its latest entry is a scheduling order of 29 January 2026.

Mochi's public statement on the litigation (April 23, 2025) says the company is "continuing to provide care" during the proceedings.

Because availability of compounded tirzepatide and semaglutide specifically is the most regulation-sensitive data point here — and is the subject of active manufacturer litigation — we'll update this section when the FDA decides on the 503B Bulks List proposal and as the federal lawsuits progress.

Mochi's home-page pricing block lists two medications by name (compounded semaglutide, compounded tirzepatide) plus a vague "treatments across skincare, hair growth, and more" line. The marketing meta-description claims "120+ conditions," but the public detail surface for non-GLP-1 categories is thin compared to the GLP-1 focus.

A /pediatrics page (see section 05), a /pharmacy page and a /medications page round out the menu. Mochi reads as a GLP-1-first platform that gestures at broader breadth, rather than a true multi-category provider in the TeleZenMD or Hims sense.

The one feature Mochi emphasizes that most competitors don't is a nutrition layer. The home page invites members to "choose a board certified medicine provider and a registered dietitian who are ready to work with you."

Mochi's FAQ is narrower. Its standard plan, Health + Medication, includes "regular video visits with a physician and health coach"; "advanced medical nutrition therapy delivered by a registered dietitian nutritionist (RDN)" is listed under the Wellness Plus plan, "Available with Qualifying Insurance." A patient paying cash should expect a health coach and ask before signing up whether a registered dietitian is part of their plan.

Whether the dietitian layer translates to better outcomes than a medication-only competitor is an open empirical question. There is solid evidence in the broader obesity-medicine literature that medication plus structured behavioral or nutritional support outperforms medication alone over the long term. Mochi's own outcome statistics (uncited, see §04) cannot answer this question; an independent randomized comparison would be required.

The category is real and the inclusion is a meaningful structural difference. Whether it earns its weight at $79/mo is a personal value call.

Reading the conflicting third-party signals. Mochi presents an unusually split external picture. Trustpilot shows a 4.5 rating across 20,135 reviews. The Better Business Bureau, by contrast, shows a 1.29-out-of-5 customer review rating across 317 reviews and 1,418 complaints filed; BBB's own note says the complaints it processes relate to cancellations. The same profile gives Mochi an A rating and has listed it as BBB Accredited since August 2026.

These instruments measure different things: Trustpilot captures self-selected user satisfaction at scale and is shaped by the company's solicitation patterns, while BBB captures complaints that escalate beyond company-internal resolution. Both are real signals. Mochi's active litigation profile — two concurrent manufacturer lawsuits, see section 06 — is a third independent signal that warrants its own weight.

Pros.

Marketplace model is real. Patients do get provider choice and pharmacy choice at the structural level — fewer competitors offer either, much less both. Stated value is meaningful even if the in-network pharmacy list isn't public.

Health coach in every plan; registered dietitian with qualifying insurance. A nutrition layer of any kind is less common in compounded GLP-1 than the medication-only model.

Large Trustpilot footprint. Trustpilot shows 20,135 reviews at 4.5.

Press footprint is broad — Mochi's home page cites mentions in Washington Post, USA Today, WSJ, Bloomberg, CNBC, Forbes, NPR, Wired, STAT, and others. Each specific story would need separate verification before propagating its content, but the breadth of trade-press attention is real.

Featured marketplace physicians check out. On 15 October 2026 Mochi's home page featured five physicians; all five are active in the public NPI Registry.

Cons and trade-offs.

BBB customer review rating is 1.29 out of 5 stars. Mochi's BBB profile shows 1.29 out of 5 across 317 customer reviews and 1,418 complaints filed. BBB's own note says the complaints relate to cancellations: health memberships and medication subscriptions are separate and must be cancelled independently. The same profile rates Mochi A and lists it as BBB Accredited since 23 August 2026.

Outcome statistics are uncited. "10% in six months for over half of members," "36 lbs avg in year one," "16% in year one" — all marketing without a footnote to any study, audit, or external source. Treat as company-stated, not as evidence.

Two concurrent manufacturer lawsuits. Mochi is defendant in: (1) Eli Lilly federal lawsuit on compounded tirzepatide (filed April 2025; it survived Mochi's motions to dismiss in part, in April and again in September 2026); (2) Novo Nordisk lawsuit on compounded semaglutide (parallel manufacturer suit). Facing suits from both manufacturers at once is itself a material consideration for new signups. See section 06 for details and sources.

In-network pharmacies are not publicly named. "Pick a pharmacy you trust" assumes the patient has trust signals to choose between options, but the home page lists no pharmacies and posts no 503A/503B classifications. The marketplace claim is structural; the transparency isn't.

Pediatric line is offered without public protocol detail. The pediatrics page names no age range, eligibility criteria, medications or consent policy. GLP-1 prescribing to children is regulatorily and editorially sensitive; that gap is a flag.

The membership fee is not on the drug pages. The medication pages say only "+ Mochi Membership"; the $79 fee and the prepaid plan prices are in the FAQ. A patient reading the drug page alone sees $60, not the $139 they will pay each month.

Featured physicians vs. marketplace pool size. Mochi names five physicians on the home page as featured examples. The actual marketplace pool — total roster, geographic coverage, and average wait time — is not disclosed. The "choose a provider" promise carries different weight at a pool of 50 vs. 500.

Compounded medications are not FDA-approved, and tirzepatide / semaglutide availability is regulation-sensitive (the FDA has not yet decided on its April 2026 proposal to exclude these drugs from the 503B Bulks List).

Mochi Health makes the most sense for the patient who wants a low all-in compounded-GLP-1 cost with a nutrition layer and who values the conceptual idea of provider choice plus pharmacy choice over the deeper transparency a single in-house operator might offer. It fits people who'd rather have a health coach — and, with qualifying insurance, a registered dietitian — than a higher-touch behavioral program, and who are comfortable with a platform that gestures at multi-category breadth without publishing the detail. The Trustpilot sample size is genuinely useful as an independent signal.

Skip it if you want named pharmacies and posted 503A/503B classifications before signing up — Mochi's marketplace transparency is at the structural level, not the in-network-detail level. Skip it if you want footnoted outcome statistics — the home-page numbers are uncited and don't survive our editorial standards. Skip it if a 1.29-out-of-5 BBB customer review rating is a deal-breaker for you.

Skip it if you want to avoid a platform with concurrent active manufacturer litigation (both Eli Lilly and Novo Nordisk) and a worker-classification class action. Skip it if you're considering pediatric weight management without specifically interrogating the protocol — the regulatory sensitivity is elevated and the public surface is thin. And skip it if you don't want a recurring membership fee — the $79 a month runs for as long as you stay, on top of the medication.

Our editorial position is to keep head-to-head verdicts in dedicated comparison pages rather than inside any single review. The shape of Mochi's position is clear enough at this level.

Against the other large-volume compounded-DTC operators (Henry Meds), Mochi has a similar Trustpilot footprint, offers a nutrition layer that Henry doesn't advertise, and has a more transparent named-physician home page. Mochi prices by dose and Henry by program, so compare the two at the dose you are prescribed. Henry has a clean 503A/503B disclosure that Mochi doesn't match.

Against the multi-category compounded operators (TeleZenMD), Mochi has a narrower real menu and a substantially larger independent-review footprint; for current prices side by side, see the GLP-1 Price Index. Against the branded-only operators (Hims, Ro), Mochi's price floor is much lower but the evidence base is weaker — compounded versus the FDA-approved branded products Hims and Ro now lean on.

The clearest case for Mochi over any of those alternatives is wanting a low all-in compounded GLP-1 cost with provider and pharmacy choice and a nutrition layer.

From Mochi Health’s public pages, read Sep 24, 2026.

Its terms refer to "certain third party pharmacies" without naming them. The about page names six physicians; the terms name the medical groups (Mochi Medical, P.A. and its California and Kansas counterparts).

Read from: Mochi terms and conditions, Mochi About.

How the other providers we cover answer the same question: which telehealth providers name their pharmacy.

How we reviewed this. Programs and process details were pulled directly from Mochi Health's public home page in June 2026. Pricing was re-checked on 6 October 2026 against Mochi's medication pages and FAQ; the onboarding flow was not entered for this review.

Prescriber verification was conducted independently against the public NPI Registry — on 15 October 2026 all five physicians featured on Mochi's home page were found individually registered and active. The featured roster had changed since our June read.

Third-party review platforms: Trustpilot shows 20,135 reviews at 4.5 — a large sample. The Better Business Bureau shows a 1.29-out-of-5 customer review rating across 317 reviews (read 12 October 2026).

Litigation history: Mochi is defendant in two concurrent matters — Eli Lilly and Company v. Mochi Health Corp. et al., No. 3:25-cv-03534 (filed 23 April 2025, N.D. Cal.; motion to dismiss the second amended complaint granted in part and denied in part on 8 September 2026, per the docket); and Novo Nordisk A/S v. Mochi Health Corp., No. 5:25-cv-06563 (filed 4 August 2025, N.D. Cal.; docket).

Clinical claims in this review are anchored to peer-reviewed primary trials (STEP 1, STEP 1 extension, SURMOUNT-1) and FDA primary sources; we do not propagate the home-page outcome statistics (10%/6mo, 36 lbs/year, 16%/year, 5-of-6 retention) as evidence — they are uncited and recorded as company-stated marketing only.

Editorial independence. PeptideWellness does not accept payment from telehealth providers, compounding pharmacies, or manufacturers in exchange for coverage, placement, or scoring. We have no commercial relationship with Mochi Health.

Editorial note: Informational only — not medical advice. Compounded medications aren't FDA-approved and don't undergo the same safety, effectiveness, or manufacturing review as branded pharmaceuticals. GLP-1 therapy decisions should be made with a licensed healthcare provider familiar with your medical history. Last reviewed June 2026.